Core Insights - Cosmo Pharmaceuticals has renewed its multi-year manufacturing and supply agreement with Takeda for the production of Mesalazine MMX 1200 mg, an oral treatment for ulcerative colitis, reinforcing its role as a key partner in global pharmaceutical production [1][2] Company Overview - Cosmo Pharmaceuticals is a life sciences company focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO) [3] - The company aims to innovate at the intersection of science and technology, with a mission to empower patients and healthcare professionals [3] Manufacturing Capabilities - The advanced manufacturing site in Lainate, Italy, is certified by multiple regulatory authorities and adheres to ISO 13485 standards, emphasizing continuous improvement and customer satisfaction [2] - The facility has been operational for over 30 years, ensuring efficient and environmentally responsible production [2] Strategic Vision - The renewal of the agreement aligns with Cosmo's Vision 2030 strategy, which focuses on scaling trusted partnerships and enhancing its leadership in the CDMO sector globally [2]